Using TRIM5α as an HIV therapeutic: the alpha gene?

Bibliography

• Cohen J. HIV prevention. Halting HIV/AIDS epidemics. Science 2011;334:1338-40
   PubMed Web of Science ®Google Scholar
• Richman DD. Introduction: challenges to finding a cure for HIV infection. Curr Opin HIV AIDS 2011;6:1-3
   PubMedGoogle Scholar
• Edgeworth RL, San JH, Rosenweig JA, et al. Vaccine development against HIV-1: current perspectives and future directions. Immunol Res 2002;25:53-74
   PubMed Web of Science ®Google Scholar
• Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26
   PubMed Web of Science ®Google Scholar
• Simoni JM, Amico KR, Smith L, et al. Antiretroviral adherence interventions: translating research findings to the real world clinic. Curr HIV AIDS Rep 2010;7:44-51
   PubMedGoogle Scholar
• Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27-34
   PubMed Web of Science ®Google Scholar
• Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: december 2010. Top HIV Med 2010;18:156-63
   PubMedGoogle Scholar
• Kuritzkes DR. Drug resistance in HIV-1. Curr Opin Virol 2011;1:582-9
   Google Scholar
• Martinez-Picado J, DePasquale MP, Kartsonis N, et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci USA 2000;97:10948-53
   PubMed Web of Science ®Google Scholar
• Winters MA, Baxter JD, Mayers DL, et al. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS. Antivir Ther 2000;5:57-63
   PubMed Web of Science ®Google Scholar
• Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000;44:2475-84
   PubMed Web of Science ®Google Scholar
• Lafeuillade A, Poggi C, Hittinger G, et al. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates. HIV Med 2001;2:231-5
   PubMedGoogle Scholar
• Henrich TJ, Tsibris AM, Lewine NR, et al. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J Acquir Immune Defic Syndr 2010;55:420-7
   PubMed Web of Science ®Google Scholar
• Tilton JC, Wilen CB, Didigu CA, et al. A maraviroc resistant HIV-1 with narrow cross- resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol 2010;84:10863-76
   PubMed Web of Science ®Google Scholar
• Baldanti F, Paolucci S, Gulminetti R, et al. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. J Med Virol 2010;82:116-22
   PubMed Web of Science ®Google Scholar
• Aiuti F and Mezzaroma I. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. AIDS Rev 2006;8:88-97
   PubMed Web of Science ®Google Scholar
• Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007;46:72-7
   PubMed Web of Science ®Google Scholar
• Ray M, Logan R, Sterne JA. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010;24:123-37
   PubMed Web of Science ®Google Scholar
• Gazzola L, Tincati C, Bellistri GM, et al. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009;48:328-37
   PubMed Web of Science ®Google Scholar
• Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002;16:1859-66
   PubMed Web of Science ®Google Scholar
• Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009;48:787-94
   PubMed Web of Science ®Google Scholar
• Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009;48:350-61
   PubMed Web of Science ®Google Scholar
• Long JL, Engels EA, Moore RD, et al. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008;22:489-96
   PubMed Web of Science ®Google Scholar
• Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011;53:1130-9
   PubMed Web of Science ®Google Scholar
• Ianello A, Samarani S, Debbeche O, et al. Potential role of IL-18 in the immunopathogenesis of AIDS, HIV-associated lipodystrophy and related clinical conditions. Curr HIV Res 2010;8:147-64
   PubMed Web of Science ®Google Scholar
• Domingo P, Estrada V, Lopez-Aldeguer J, et al. Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev 2012;14:112-23
   PubMed Web of Science ®Google Scholar
• Strayer DS, Akkina R, Bunnell BA, et al. Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther 2005;11:823-41
   PubMed Web of Science ®Google Scholar
• Humeau LM, Binder GK, Lu X, et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 2004;9:902-13
   PubMed Web of Science ®Google Scholar
• Mitsuyasu RT, Merigan TC, Carr A, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 2009;15:285-92
   PubMed Web of Science ®Google Scholar
• DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010;2:36ra43
   PubMed Web of Science ®Google Scholar
• Kiem HP, Jerome KR, Deeks SG, et al. Hematopoietic stem cell based gene therapy for HIV disease. Cell Stem Cell 2012;10:137-47
   PubMed Web of Science ®Google Scholar
• Podsakoff GM, Engel BC, Carbonaro DA, et al. Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther 2005;12:77-86
   PubMed Web of Science ®Google Scholar
• Walker JE, Chen RX, McGee J, et al. In vivo inhibition of HIV-1 infection and maintenance of normal human CD4+ cell levels by a triple combination ant-HIV gene therapy into hematopoietic stem cells. J Virol 2012;86:5719-29
   PubMed Web of Science ®Google Scholar
• Keller G. Hematopoietic stem cells. Curr Opin Immunol 1992;4:133-9
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Kurtzberg J, Gluckman E, et al. Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation. Blood Cells 1991;17:313-29
   PubMedGoogle Scholar
• Kohn DB. Gene therapy using hematopoietic stem cells. Curr Opin Mol Ther 1999;1:437-42
   PubMed Web of Science ®Google Scholar
• Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-8
   PubMed Web of Science ®Google Scholar
• Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 1996;86:267-77
   Google Scholar
• Huang Y, Paxton WA, Wolilnsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-3
   PubMed Web of Science ®Google Scholar
• Naif HM, Cunningham AL, Alali M, et al. A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5Δ32 exhibits dual tropism by infecting macrophages and MT2 cells via CXCR4. J Virol 2002;76:3114-24
   PubMed Web of Science ®Google Scholar
• Hutter G and Thiel E. Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. AIDS 2011;25:273-5
   PubMed Web of Science ®Google Scholar
• Kohn DB, Bauer G, Rice CR, et al. A clinical trial of retroviral-mediated transfer of a rev- responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 1999;94:368-71
   PubMed Web of Science ®Google Scholar
• ter Brake O, Legrand N, von Eije KJ, et al. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model. Gene Ther 2009;16:148-53
   PubMed Web of Science ®Google Scholar
• Swan CH, Buhler B, Steinberger P, et al. T cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 2006;13:1480-92
   PubMed Web of Science ®Google Scholar
• Urnov FD, Rebar EJ, Holmes MC, et al. Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010;11:636-46
   PubMed Web of Science ®Google Scholar
• Anderson JS, Javien J, Nolta JA, et al. Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5alpha protein, a CCR5 shRNA, and a TAR decoy. Mol Ther 2009;17:2103-14
   PubMed Web of Science ®Google Scholar
• Anderson J, Akkina R. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection. Gene Ther 2007;14:1287-97
   PubMed Web of Science ®Google Scholar
• Anderson J, Akkina R. Human immunodeficiency virus type 1 restriction by human- rhesus chimeric tripartite motif 5 alpha (TRIM5alpha) in CD34(+) cell-derived macrophages in vitro and in T cells in vivo in severe combined immunodeficient (SCID-hu) mice transplanted with human fetal tissue. Hum Gene Ther 2008;19:217-28
   PubMed Web of Science ®Google Scholar
• Boden D, Pusch O, Lee F, et al. Human immunodeficiency virus type 1 escape from RNA interference. J Virol 2003;77:11531-5
   PubMed Web of Science ®Google Scholar
• Stremlau M, Owens CM, Perron MJ, et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004;427:848-53
   PubMed Web of Science ®Google Scholar
• Song B, Javanbakht H, Perron M, et al. Retrovirus restriction by TRIM5alpha variants from old world and new world primates. J Virol 2005;79:3930-7
   PubMed Web of Science ®Google Scholar
• Perron MJ, Stremlau M, Song B, et al. TRIM5alpha mediates the postentry block to N- tropic murine leukemia viruses in human cells. Proc Natl Acad Sci USA 2004;101:11827-32
   PubMed Web of Science ®Google Scholar
• Yap MW, Nisole S, Lynch C, et al. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA 2004;101:10786-91
   PubMed Web of Science ®Google Scholar
• Keckesova Z, Ylinen LM, Towers GJ. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci USA 2004;101:10780-5
   PubMed Web of Science ®Google Scholar
• Ulm JW, Perron M, Sodroski J, et al. Complex determinants within the Moloney murine leukemia virus capsid modulate susceptibility of the virus to Fv1 and Ref1 mediated restriction. Virology 2007;363:245-55
   PubMed Web of Science ®Google Scholar
• Hatziioannou T, Perez-Caballero D, Yang A, et al. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci USA 2004;101:10774-9
   PubMed Web of Science ®Google Scholar
• Anderson J, Akkina R. TRIM5alpha(rh) expression restricts HIV-1 infection in lentiviral vector transduced CD34+ cell derived macrophages. Mol Ther 2005;12:687-96
   PubMed Web of Science ®Google Scholar
• Nisole S, Stoye JP, Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 2005;3:799-808
   PubMed Web of Science ®Google Scholar
• Berthoux L, Sebastian S, Sayah DM, et al. Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues. J Virol 2005;79:7883-8
   PubMed Web of Science ®Google Scholar
• Berthoux L, Sebastian S, Sokolskaja E, et al. Cyclophilin A is required for TRIM5{alpha} mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci USA 2005;102:14849-53
   PubMed Web of Science ®Google Scholar
• Sayah DM, Sokolskaja E, Berthoux L, et al. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 2004;430:569-73
   PubMed Web of Science ®Google Scholar
• Pertel T, Hausmann S, Morger D, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 2011;472:361-5
   PubMed Web of Science ®Google Scholar
• Li X, Gold B, O’hUigin C, et al. Unique features of TRIM5alpha among closely related human TRIM family members. Virology 2007;360:419-33
   PubMed Web of Science ®Google Scholar
• Stermlau M, Perron M, Welikala S, et al. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus. J Virol 2005;79:3139-45
   PubMed Web of Science ®Google Scholar
• Biris N, Yang Y, Taylor AB, et al. Structure of the rhesus monkey TRIM5alpha PRYSPRY domain, the HIV capsid recognition module. Proc Natl Acad Sci USA 2012;109:13278-83
   PubMed Web of Science ®Google Scholar
• Yang H, Ji X, Zhao G, et al. Structural insight into HIV-1 capsid recognition by rhesus TRIM5alpha. Proc Natl Acad Sci USA 2012;109:18372-7
   PubMed Web of Science ®Google Scholar
• Javanbakht H, Yuan W, Yeung DF, et al. Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding. Virology 2006;353:234-46
   PubMed Web of Science ®Google Scholar
• Perron MJ, Stremlau M, Lee M, et al. The human TRIM5_ restriction factor mediates accelerated uncoating of the N-Tropic murine leukemia virus capsid. J Virol 2007;81:2138-48
   PubMed Web of Science ®Google Scholar
• Sakuma R, Noser JA, Ohmine S, et al. Rhesus monkey TRIM5a restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nat Med 2007;13:631-5
   PubMed Web of Science ®Google Scholar
• Maegawa H, Miyamoto MH, Sakuragi J, et al. Contribution of RING domain to retrovirus restriction by TRIM5alpha depends on combination of host and virus. Virology 2010;399:212-20
   PubMed Web of Science ®Google Scholar
• Li Y, Li X, Stremlau M, et al. Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. J Virol 2006;80:6738-44
   PubMed Web of Science ®Google Scholar
• Sawyer SL, Wu LI, Emerman M, et al. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci USA 2005;102:2832-7
   PubMed Web of Science ®Google Scholar
• Yap MW, Nisole S, Stoye JP. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 2005;15:73-8
   PubMed Web of Science ®Google Scholar
• Pham QT, Bouchard A, Grutter MG, et al. Generation of human TRIM5alpha mutants with high HIV-1 restriction activity. Gene Ther 2010;17:859-71
   PubMed Web of Science ®Google Scholar
• Neagu MR, Ziegler P, Pertel T, et al. Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J Clin Invest 2009;119:3035-47
   PubMed Web of Science ®Google Scholar
• Chan E, Schaller T, Eddaoudi A, et al. Lentiviral gene therapy against human immunodeficiency virus type 1, using a novel human TRIM21-cyclophilin A restriction factor. Hum Gene Ther 2012;23:1-10
   PubMedGoogle Scholar
• Diaz-Griffeo F, Vandegraaff N, Li Y, et al. Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1. Virology 2006;351:404-19
   PubMed Web of Science ®Google Scholar
• Towers GJ. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 2007;4:40
   PubMedGoogle Scholar
• Diaz-Griffero F, Kar A, Lee M, et al. Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. Virology 2007;369:400-10
   PubMed Web of Science ®Google Scholar
• Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994;372:359-62
   PubMed Web of Science ®Google Scholar
• Brennan G, Kozyrev Y, Hu S-L. TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis. Proc Natl Acad Sci USA 2008;105:3569-74
   PubMed Web of Science ®Google Scholar
• Newman RM, Hall L, Kirmaier A, et al. Evolution of TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog 2008;4:e1000003
   PubMedGoogle Scholar
• Virgen CA, Kratovac Z, Bieniasz PD, et al. Independent genesis of chimeric TRIM5- cyclophilin proteins in two primate species. Proc Natl Acad Sci USA 2008;105:3563-8
   PubMed Web of Science ®Google Scholar
• Wilson SJ, Webb BLJ, Ylinen LMJ, et al. Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc Natl Acad Sci USA 2008;105:3557-62
   PubMed Web of Science ®Google Scholar
• Pacheco B, Finzi A, Stremlau M, et al. Adaptation of HIV-1 to cells expressing rhesus monkey TRIM5alpha. Virology 2010;408:204-12
   PubMed Web of Science ®Google Scholar
• Sakuma JA, Noser JA, Ohmine S, et al. Inhibition of HIV-1 replication by simian restriction factors. Gene Ther 2007;14:185-9
   PubMed Web of Science ®Google Scholar
• Voit RA, McMahon MA, Sawyer SL, et al. Generation of an HIV resistant T-cell line by targeted “Stacking” of restriction factors. Mol Ther 2013; [Epub ahead of print]
   Web of Science ®Google Scholar